antiEGFR-CD3 CSANs

antiEGFR-CD3 CSANs (Chemically Self-Assembled Nanorings) are a novel class of multivalent, bispecific T-cell engagers developed by the Wagner Lab at the University of Minnesota. These constructs utilize a non-genetic approach to facilitate selective cell-cell interactions by self-assembling into nanorings functionalized with single-chain antibody fragments (scFv) targeting the Epidermal Growth Factor Receptor (EGFR) and the CD3 epsilon subunit of the T-cell receptor complex. By cross-linking T cells to EGFR-overexpressing malignant cells, such as those found in glioblastoma and medulloblastoma, the CSANs induce T-cell activation and targeted cytotoxicity. This platform is designed to offer a reversible and potentially safer alternative to permanent genetic engineering approaches like CAR-T cells, with the ability to cross the blood-brain barrier for the treatment of CNS solid tumors.

Other names

anti-EGFR-CD3 chemically self-assembling nanoringsanti-EGFR-CD-3 chemically self-assembling nanoringsanti-EGFR-CD 3 chemically self-assembling nanorings